NSE: SUNPHARMA · 21 October 2026
- SUN PHARMACEUTICAL IND L (SUNPHARMA) traded down 0.17% at ₹1,740.10, moving within a day's range of ₹1,734.60 to ₹1,755.00 after opening at ₹1,747.00.
- Sun Pharma announced that UNLOXCYT (cosibelimab-ipdl) has been elevated to a National Comprehensive Cancer Network Category 2A recommended option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation. The submission was backed by pivotal registration study data demonstrating durable objective and complete responses with a low incidence of high-grade immune-mediated adverse reactions. This designation expands its clinical utility and supports healthcare access and physician evaluation in advanced skin cancer care.
- Trading volume was 0.29 times the 20-day average daily volume.
Why is Sun Pharmaceutical Ind L share price falling on 21 October 2026?
SUN PHARMACEUTICAL IND L (SUNPHARMA) traded down 0.17% at ₹1,740.10, moving within a day's range of ₹1,734.60 to ₹1,755.00 after opening at ₹1,747.00.
The broader market showed positive momentum as the Nifty index rose 0.36%, whereas the Nifty Pharma sector benchmark lagged with a decline of 0.56%. Sun Pharma's modest intraday dip aligns with the softer sector trend, reflecting mild pressure across pharmaceutical peers despite positive broader market conditions, while its recent multi-day performance shows returns of -1.73% over the past 5 trading days and -6.89% over the past 20 trading days.
Company disclosures provide ongoing context as Sun Pharma recently announced that its specialty product UNLOXCYT received a Category 2A preferred designation in the updated NCCN guidelines for locally advanced cutaneous squamous cell carcinoma, following recent credit rating assignments from CRISIL and ICRA acknowledging its proposed business expansions and strong financial profile. While these updates highlight steady operational progress in innovative medicines, they serve as background context rather than direct proven drivers for today's minor price adjustment.
4.38 lakh shares traded by 21 October 2026 · 11:00 AM IST. This compares with a 20-day average daily volume of 15.21 lakh shares (0.29 times). The five-day average daily volume was 13.46 lakh shares. Separately, the NSE report for 19 October 2026 showed 4.47 lakh shares delivered, representing 53.92% of that day’s traded volume. The same report recorded 48,891 trades.
The stock drifted down 0.17% in light trading volume that ran well below its 20-day average, closely mirroring the broader Nifty Pharma sector's decline of 0.56% rather than reacting to any specific single catalyst.
Latest Company Developments
Sun Pharma announced that UNLOXCYT (cosibelimab-ipdl) has been elevated to a National Comprehensive Cancer Network Category 2A recommended option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation. The submission was backed by pivotal registration study data demonstrating durable objective and complete responses with a low incidence of high-grade immune-mediated adverse reactions. This designation expands its clinical utility and supports healthcare access and physician evaluation in advanced skin cancer care.
Regulatory and clinical guideline updates strengthen the adoption profile and market reach of Sun Pharma's innovative oncology medicines portfolio in global markets.
CRISIL and ICRA assigned ratings to the company's proposed non-convertible debenture programme of up to ₹10,000 crore while reaffirming existing credit facilities at CRISIL AAA/Stable and ICRA AAA/Stable. The rating rationales factor in Sun Pharma's market leadership in domestic formulations, robust specialty product pipeline, and the financial impact of the proposed acquisition of Organon & Co. The agencies note that strong annual cash generation will support subsequent deleveraging following transaction completion.
Favorable credit ratings underscore the company's strong financial risk profile and debt-servicing capacity as it undertakes major strategic expansions.
The company announced that Mr. Gautam Doshi tendered his resignation as a Non-Executive, Independent Director effective October 12, 2026, citing personal commitments. He confirmed that there are no other material reasons for his departure. The board took note of the resignation during its meeting held the same day.
Board and management continuity updates matter for corporate governance, although routine director departures do not directly explain short-term share price movements.
'Completion and Result of Postal Ballot dated 25 August 2026'.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 13.01% on 30 September 2026. This compares with 12.84% on 30 June 2026, a change of +0.17 percentage points.
The filing reported 51 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Upcoming second-quarter financial results scheduled for announcement on October 30, 2026
- Progress on the integration planning and regulatory approvals for the proposed Organon & Co. acquisition
- Commercialization updates and market uptake for newly launched specialty products like UNLOXCYT and Leqselvi
- Delivery volume trends and cash participation relative to the 20-day average volume
Other Dated Coverage
- Sun Pharma in Focus After CRISIL and ICRA Assign NCD Ratings | 15 October 2026 — 15 October 2026
- Sun Pharma in Focus After NCD Issuance Approval and Director Resignation | 14 October 2026 — 14 October 2026
- Sun Pharma in Focus After INR 10,000 Crore NCD Approval and Director Resignation | 13 October 2026 — 13 October 2026
More Sun Pharmaceutical Ind L news and dated analysis →
Frequently Asked Questions
What is the latest Sun Pharmaceutical Ind L company news?
Sun Pharma announced that UNLOXCYT (cosibelimab-ipdl) has been elevated to a National Comprehensive Cancer Network Category 2A recommended option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation. The submission was backed by pivotal registration study data demonstrating durable objective and complete responses with a low incidence of high-grade immune-mediated adverse reactions. This designation expands its clinical utility and supports healthcare access and physician evaluation in advanced skin cancer care.
How strong was Sun Pharmaceutical Ind L’s trading volume?
4.38 lakh shares traded, 0.29 times the 20-day average daily volume. The price and volume data are dated 21 October 2026 · 11:00 AM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.